Colorectal Liver Metastases

  • H.-J. Gassel
  • M. Gasser
  • A.M. Waaga-Gasser
  • W. Timmermann


The liver is the main site of manifestation of métastases of colorectal neoplasms. Diagnostic examination must address the primary tumor site, the extent of liver involvement and the presence of extrahepatic disease by endoscopy, ultrasound, computed tomography, chest x-ray and carcinogenic antigen (CEA) level assessment. Surgical resection represents the treatment of choice and is the only curative therapy at present. It should be performed for resectable métastases after exclusion of extrahepatic tumor (except pulmonary métastases), if the patient’s general health status and the remaining liver parenchyma are functionally sufficient. The achievement of a Ro status is the main prognostic factor. Adjuvant and neoadjuvant treatment protocols are under current investigation and cannot be recommended unless in clinical trials. Palliative options include chemotherapy (at present gold standard) and local ablative procedures, e.g. by radiofrequency or laser induced thermoablation and cryoablation. A close follow-up of the patients is necessary since secondary treatment can prolong survival.


Liver Metastasis Liver Resection Colorectal Liver Metastasis Folinic Acid Colorectal Metastasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Scheele J, Stang R, Altendorf-Hofmann A, Paul M (1995) Resection of colorectal liver métastases. World J Surg 19(1): 59–71PubMedCrossRefGoogle Scholar
  2. 2.
    Berman RS, Portera CA Jr, Ellis LM. (2001) Biology of liver métastases. Cancer Treat Res 109: 183–206PubMedGoogle Scholar
  3. 3.
    Nordlinger B, Guiguet M, Vaillant JC, et al. (1996) Surgical resection of colorectal carcinoma métastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77(7):1254–1262Google Scholar
  4. 4.
    Adam R, Laurent A, Azoulay D, et al. (2000) Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 232:777–785PubMedCrossRefGoogle Scholar
  5. 5.
    Seifert JK, Achenbach T, Heintz A et al. (2000) Cryotherapy for liver métastases. Int J Colorectal Dis 15:161–166PubMedCrossRefGoogle Scholar
  6. 6.
    Curley SA, Izzo F, Delrio P et al. (1999) Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 230:1–8PubMedCrossRefGoogle Scholar
  7. 7.
    Vogl TJ, Müller PK, Mack MG et al. (1999) Liver métastases: interventional therapeutic techniques and results, state of the art. Eur Radiol 9:675–684PubMedCrossRefGoogle Scholar
  8. 8.
    Kemeny N, Fata F (2001) Hepatic-arterial chemotherapy. Lancet Oncol 2:418–428PubMedCrossRefGoogle Scholar
  9. 9.
    Lorenz M, Mueller HH, Mattes F et al. (2001) Phase II study of weekly 24-hour intraarterial high-dose infusion of 5-fluorouracil and folinic acid for liver métastases from colorectal carcinomas. Ann Oncol 12:321–325PubMedCrossRefGoogle Scholar
  10. 10.
    Elias D, Cavalcanti A, Sabourin JC, et al. (1998) Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal métastases. J Surg Oncol 69(2):88–93.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • H.-J. Gassel
    • 1
  • M. Gasser
    • 1
  • A.M. Waaga-Gasser
    • 2
  • W. Timmermann
    • 3
  1. 1.Bayerische Julius-Maximilians-Universität, Chirurgische UniversitätsklinikWürzburgGermany
  2. 2.Abt. für Molekulare Onkologie and ImmunologieBayerische Julius-Maximilians-Universität, Chirurgische UniversitätsklinikWürzburgGermany
  3. 3.Bayerische Julius-Maximilians-Universität, Chirurgische UniversitätsklinikWürzburgGermany

Personalised recommendations